



## **PHOST'IN THERAPEUTICS IS AWARDED €3.2M THROUGH THE FRANCE 2030 INVESTMENT PLAN TO PIONEER N-GLYCOSYLATION INHIBITORS AGAINST CHRONIC FIBROSIS**

*Montpellier, France – September 8<sup>th</sup>, 2025*

**Phost'in Therapeutics SAS (Montpellier, France), a clinical-stage biotechnology company specialized in the discovery and development of N-glycosylation inhibitors for the treatment of cancer and other serious diseases; announced today that it has been selected as a laureate of the national I-DEMO Call for Projects to accelerate the development of its GlyPANASH program targeting chronic fibrosis. Phost'in will receive €3.2 million in non-dilutive funding through the France 2030 Plan, managed by Bpifrance on behalf of the French government.**

Phost'in is developing a novel class of compounds that modulate abnormal glycosylation. Its lead candidate, PhOx430, is the only known selective inhibitor of the N-glycosylation enzyme GnT-V. Initially developed in oncology for fighting advanced solid tumors, PhOx430 successfully entered clinical trials in 2022 (PhAST trial) and recently reached an important milestone with the opening of two expansion cohorts. In parallel, preclinical studies have demonstrated the drug's potential in several in vivo models of fibrosis.

Fibrosis is a progressive and irreversible pathological process in which healthy tissue is replaced by a stiff, disorganized extracellular matrix, leading to organ dysfunction and failure. The disease burden is significant, particularly in the liver, kidney, and heart, with 1 out of 4, 1 out of 6, and 1 out of 60 people; respectively, affected worldwide. Chronic Kidney Disease (CKD), Heart Failure (HF), and Non-Alcoholic Steatohepatitis (NASH) are among the most prevalent forms of fibrosis – and have limited therapeutic options. Phost'in's product pipeline aims to directly target fibrosis development - rather than managing its symptoms. Through the GlyPANASH project, the I-DEMO funding will enable the company to complete a Phase I trial in healthy volunteers to demonstrate the safety of PhOx430 for non-cancer related chronic indications; and, to advance a second drug candidate.

Karine Chorro, CEO of Phost'in Therapeutics, commented: *"We are truly excited to receive this significant support from the France 2030 I-DEMO program. It reinforces our vision to establish N-glycosylation inhibitors as a new therapeutic standard for chronic fibrosis. With convenient oral delivery and minimal side effects, we are more motivated than ever to improve the lives of patients suffering from serious chronic diseases."*

### **About Phost'in Therapeutics**

Phost'in Therapeutics is a French biotechnology company specialized in the discovery and development of NCEs specifically targeting abnormal pathological **glycosylation mechanisms for the treatment of serious chronic diseases. Its lead candidate, PhOx430, is currently in clinical development in oncology. In addition, the company conducts** upstream research programs in several other diseases, leveraging its unique expertise and proprietary discovery platform. A spin-off of the academic world, Phost'in possesses, in addition to its own patents, an exclusive license for two families of academic patents owned by CNRS (Centre National de



la Recherche Scientifique), ENSCM (École Nationale Supérieure de Chimie de Montpellier), and the Universities of Montpellier, Sorbonne Paris Nord, and Paris-Saclay. Based in Montpellier, France, the company has received the renewed support of the French Government, France 2030, Bpifrance, the life sciences cluster Eurobiomed, the Occitanie Region, and Montpellier Med Vallée.

#### **About France 2030 and I-DEMO**

The France 2030 investment plan is a national initiative aimed at accelerating innovation and strengthening France's leadership in strategic sectors. The I-DEMO Call for Project, launched as part of this plan, supports highly innovative R&D projects with strong industrial potential by funding the demonstration phase of breakthrough technologies. Focused on sectors such as healthcare, energy, environment, and digital, I-DEMO enables companies to validate cutting-edge solutions that have the potential to create significant future impact

**For more information about Phost'in Therapeutics, please visit [www.phostin.com](http://www.phostin.com) and/or contact:**

***Karine Chorro, CEO & Richard Meadows, CBO***

***[contact@phostin.com](mailto:contact@phostin.com)***

***Phost'in Therapeutics SAS, 104 rue de la Galera, 34 090 Montpellier FRANCE***